Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of TQC2731 in adults with inadequately controlled severe asthma
CTR20244307Phase 3Active
- Sponsor
- Nanjing Shunxin Pharmaceutical
- Start
- Mar 2025
- Modality
- IgG Antibodies → Naked Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of bosakitug in severe asthma, sponsored by Nanjing Shunxin Pharmaceutical. Started Mar 2025; status: active.
02
Drugs
bosakitug
03
Conditions
severe asthma
Beyond the preview
Go deeper on CTR20244307.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244307.